Liver disease, critical illness, platelet function Haematological Disorders
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Current participant inclusion criteria as of 24/05/2024: 1. Admitted to ICU at the Royal Berkshire Hospital 2. Aged 18 years old and above 3. Evidence of established liver disease, or acute liver dysfunction related to underlying illness, as determined by the clinicians caring for the patient at the time of eligibility assessment. Previous participant inclusion criteria: 1. Known liver disease or 2. Acute liver dysfunction
Exclusion criteria
Exclusion criteria: 1. Patients on P2Y12 inhibitors (including clopidogrel, ticagrelor and prasugrel) 2. Patients on treatment-dose anticoagulation, including warfarin or novel anticoagulant drugs 3. Patients under 18 years of age 4. Active or recent malignancy (< 1 year) or on active treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Platelet reactivity measured using Platelet Phenomics Analysis (Flow Cytometry and Thrombus formation under flow) combined with mathematical analysis, correlated according to liver disease type, burden, and stage, in blood collected during the study | — |
Secondary
| Measure | Time frame |
|---|---|
| The following secondary outcome measures will be assessed in blood collected during the study: 1. Thrombus size generated measured using an in vitro thrombus formation assay 2. Clotting parameters measured using thromboelastography and related haemostatic assays 3. Platelet receptor levels measured using flow cytometry 4. Signalling protein absolute levels and phosphorylation state measured using proteomic analysis 5. Signalling-pathway-specific experiments including modelling changes in cell lines | — |
Countries
England, United Kingdom